Global Hemophilia Market 2014-2018

DUBLIN, April 17, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/fclw7g/global_hemophilia) has announced the addition of the "Global Hemophilia Market 2014-2018" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )


The analysts forecast the Global Hemophilia market to grow at a CAGR of 6.07 percent over the period 2013-2018. One of the key factors contributing to this market growth is the development of new hemophilia therapeutics. The Global Hemophilia market has also been witnessing the increase in technological innovations. However, the high cost of hemophilia therapeutics could pose a challenge to the growth of this market.

The report, the Global Hemophilia Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Hemophilia market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Currently, most of the therapeutic hemophilia products are short acting, i.e., used only for when the patient suffers from bleeding. Further, many of these products exhibit immunogenic reactions resulting in a reduced effect of the therapeutic. In order to mitigate these issues, technologies such as PEGylation, recombinant DNA, and protein fusion technology, were developed and applied in the production of new therapies with a longer life span and fewer immunogenic reactions.

For example, Biogen Idec is developing a next generation Hemophilia A therapy. The firm's leading therapeutic product, rFVIIIFc, is a recombinant - a truncated version of factor VIII, fused to the Fc domain of an antibody to extend half-life in the bloodstream. The resultant recombinant product is a result of Biogen's protein fusion technology. Thus, increase in technological innovations is expected to drive the Global Hemophilia market during the forecast period.

According to the report, one of the major drivers in this market is the increase in the development of new hemophilia therapeutics. Currently, there are large number of products in the pipeline being developed by vendors which are aimed at addressing Hemophilia A, Hemophilia B, and von WilleBrand disease. The anticipated approval of these pipeline products is expected to contribute to the growth of the market during the forecast period.

Further, the report states that one of the major challenges in this market is the high cost of hemophilia therapeutics. The high cost is attributed to the longer time taken to manufacture hemophilia prophylactics and manufacturing constraints.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Hemophilia Product Pipeline

08. Market Segmentation of Hemophilia Market by Type

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

18. Key Vendor Analysis

19. Other Reports in this Series

Companies Mentioned: 

• Baxter International Inc.
• Bayer AG.
• Biogen Idec
• CSL Behring LLC.
• Grifols S.A
• Inspiration Biopharmaceuticals Inc.
• Kedrion Biopharma Inc.
• Novo Nordisk A/s-b.
• Octapharma AG.
• Pfizer Inc.
• Swedish Orphan Biovitrum AB.

For more information visit http://www.researchandmarkets.com/research/fclw7g/global_hemophilia

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

SOURCE Research and Markets